Verastem, Inc. (VSTM)

Market Cap	285.19M
Revenue (ttm)	10.00M
Net Income (ttm)	-148.88M
Shares Out	54.95M
EPS (ttm)	-3.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,610,613
Open	5.30
Previous Close	5.31
Day's Range	5.16 - 5.43
52-Week Range	2.10 - 9.10
Beta	0.85
Analysts	Strong Buy
Price Target	12.71 (+144.89%)
Earnings Date	Aug 7, 2025

About VSTM

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 27, 2012
• Employees: 78
• Stock Exchange: NASDAQ
• Ticker Symbol: VSTM
• Website: https://www.verastem.com

Analyst Forecast

According to 8 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price forecast is $12.71, which is an increase of 144.89% from the latest price.

Price Target

$12.71

(144.89% upside)

Analyst Consensus: Strong Buy